Cargando…

Genome Editing among Bioethics and Regulatory Practices

In the last decade, genome editing technologies became very effective and several clinical trials have been started in order to use them for treating some genetic diseases. Interestingly, despite more than 50 years of discussion about the frontiers of genetics in human health and evolution, the deba...

Descripción completa

Detalles Bibliográficos
Autor principal: Mandrioli, Mauro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8774098/
https://www.ncbi.nlm.nih.gov/pubmed/35053161
http://dx.doi.org/10.3390/biom12010013
_version_ 1784636254789304320
author Mandrioli, Mauro
author_facet Mandrioli, Mauro
author_sort Mandrioli, Mauro
collection PubMed
description In the last decade, genome editing technologies became very effective and several clinical trials have been started in order to use them for treating some genetic diseases. Interestingly, despite more than 50 years of discussion about the frontiers of genetics in human health and evolution, the debate about the bioethics and the regulatory practices of genome editing is still far from satisfactory answers. This delay results from an excessive emphasis on the effectiveness of the genome editing technologies that is relevant for the regulatory practices, but not at a bioethical level. Indeed, other factors (such as accessibility and acceptability) could make these techniques not accepted at the bioethical level, even in the presence of their 100% effectiveness.
format Online
Article
Text
id pubmed-8774098
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-87740982022-01-21 Genome Editing among Bioethics and Regulatory Practices Mandrioli, Mauro Biomolecules Review In the last decade, genome editing technologies became very effective and several clinical trials have been started in order to use them for treating some genetic diseases. Interestingly, despite more than 50 years of discussion about the frontiers of genetics in human health and evolution, the debate about the bioethics and the regulatory practices of genome editing is still far from satisfactory answers. This delay results from an excessive emphasis on the effectiveness of the genome editing technologies that is relevant for the regulatory practices, but not at a bioethical level. Indeed, other factors (such as accessibility and acceptability) could make these techniques not accepted at the bioethical level, even in the presence of their 100% effectiveness. MDPI 2021-12-22 /pmc/articles/PMC8774098/ /pubmed/35053161 http://dx.doi.org/10.3390/biom12010013 Text en © 2021 by the author. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Mandrioli, Mauro
Genome Editing among Bioethics and Regulatory Practices
title Genome Editing among Bioethics and Regulatory Practices
title_full Genome Editing among Bioethics and Regulatory Practices
title_fullStr Genome Editing among Bioethics and Regulatory Practices
title_full_unstemmed Genome Editing among Bioethics and Regulatory Practices
title_short Genome Editing among Bioethics and Regulatory Practices
title_sort genome editing among bioethics and regulatory practices
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8774098/
https://www.ncbi.nlm.nih.gov/pubmed/35053161
http://dx.doi.org/10.3390/biom12010013
work_keys_str_mv AT mandriolimauro genomeeditingamongbioethicsandregulatorypractices